nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000553	0.000553	CcSEcCtD
Temozolomide—Weight decreased—Prednisone—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Temozolomide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000549	0.000549	CcSEcCtD
Temozolomide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Temozolomide—Dizziness—Captopril—systemic scleroderma	0.000544	0.000544	CcSEcCtD
Temozolomide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000542	0.000542	CcSEcCtD
Temozolomide—Depression—Prednisone—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Temozolomide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00054	0.00054	CcSEcCtD
Temozolomide—Urticaria—Leflunomide—systemic scleroderma	0.000539	0.000539	CcSEcCtD
Temozolomide—Abdominal pain—Leflunomide—systemic scleroderma	0.000536	0.000536	CcSEcCtD
Temozolomide—Body temperature increased—Leflunomide—systemic scleroderma	0.000536	0.000536	CcSEcCtD
Temozolomide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Temozolomide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Temozolomide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Temozolomide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000532	0.000532	CcSEcCtD
Temozolomide—Breast disorder—Methotrexate—systemic scleroderma	0.000532	0.000532	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000531	0.000531	CcSEcCtD
Temozolomide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000531	0.000531	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00053	0.00053	CcSEcCtD
Temozolomide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000529	0.000529	CcSEcCtD
Temozolomide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000529	0.000529	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000529	0.000529	CcSEcCtD
Temozolomide—Insomnia—Lisinopril—systemic scleroderma	0.000527	0.000527	CcSEcCtD
Temozolomide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000526	0.000526	CcSEcCtD
Temozolomide—Paraesthesia—Lisinopril—systemic scleroderma	0.000523	0.000523	CcSEcCtD
Temozolomide—Vomiting—Captopril—systemic scleroderma	0.000523	0.000523	CcSEcCtD
Temozolomide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000521	CcSEcCtD
Temozolomide—Dyspnoea—Lisinopril—systemic scleroderma	0.00052	0.00052	CcSEcCtD
Temozolomide—Rash—Captopril—systemic scleroderma	0.000519	0.000519	CcSEcCtD
Temozolomide—Dermatitis—Captopril—systemic scleroderma	0.000518	0.000518	CcSEcCtD
Temozolomide—Somnolence—Lisinopril—systemic scleroderma	0.000518	0.000518	CcSEcCtD
Temozolomide—Headache—Captopril—systemic scleroderma	0.000516	0.000516	CcSEcCtD
Temozolomide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Temozolomide—Dyspepsia—Lisinopril—systemic scleroderma	0.000513	0.000513	CcSEcCtD
Temozolomide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000512	0.000512	CcSEcCtD
Temozolomide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000512	0.000512	CcSEcCtD
Temozolomide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000511	0.000511	CcSEcCtD
Temozolomide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000511	0.000511	CcSEcCtD
Temozolomide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Temozolomide—Decreased appetite—Lisinopril—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000503	0.000503	CcSEcCtD
Temozolomide—Fatigue—Lisinopril—systemic scleroderma	0.000503	0.000503	CcSEcCtD
Temozolomide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Temozolomide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.0005	0.0005	CcSEcCtD
Temozolomide—Hypersensitivity—Leflunomide—systemic scleroderma	0.0005	0.0005	CcSEcCtD
Temozolomide—Constipation—Lisinopril—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Temozolomide—Pain—Lisinopril—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Temozolomide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000496	0.000496	CcSEcCtD
Temozolomide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000494	0.000494	CcSEcCtD
Temozolomide—Diarrhoea—Azathioprine—systemic scleroderma	0.000491	0.000491	CcSEcCtD
Temozolomide—Haemoglobin—Prednisone—systemic scleroderma	0.00049	0.00049	CcSEcCtD
Temozolomide—Nausea—Captopril—systemic scleroderma	0.000489	0.000489	CcSEcCtD
Temozolomide—Haemorrhage—Prednisone—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Temozolomide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Temozolomide—Asthenia—Leflunomide—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Temozolomide—Hallucination—Prednisone—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Temozolomide—Pancytopenia—Methotrexate—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Temozolomide—Feeling abnormal—Lisinopril—systemic scleroderma	0.00048	0.00048	CcSEcCtD
Temozolomide—Pruritus—Leflunomide—systemic scleroderma	0.00048	0.00048	CcSEcCtD
Temozolomide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Temozolomide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000477	0.000477	CcSEcCtD
Temozolomide—Neutropenia—Methotrexate—systemic scleroderma	0.000476	0.000476	CcSEcCtD
Temozolomide—Dysuria—Methotrexate—systemic scleroderma	0.000476	0.000476	CcSEcCtD
Temozolomide—Dizziness—Azathioprine—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000473	0.000473	CcSEcCtD
Temozolomide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000469	0.000469	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Temozolomide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Temozolomide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Temozolomide—Diarrhoea—Leflunomide—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Temozolomide—Urticaria—Lisinopril—systemic scleroderma	0.000463	0.000463	CcSEcCtD
Temozolomide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000462	0.000462	CcSEcCtD
Temozolomide—Abdominal pain—Lisinopril—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Temozolomide—Body temperature increased—Lisinopril—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Temozolomide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000459	0.000459	CcSEcCtD
Temozolomide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Temozolomide—Vomiting—Azathioprine—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Temozolomide—Pneumonia—Methotrexate—systemic scleroderma	0.000456	0.000456	CcSEcCtD
Temozolomide—Eye disorder—Prednisone—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Temozolomide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Temozolomide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Temozolomide—Infestation NOS—Methotrexate—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Temozolomide—Infestation—Methotrexate—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Temozolomide—Rash—Azathioprine—systemic scleroderma	0.000453	0.000453	CcSEcCtD
Temozolomide—Dermatitis—Azathioprine—systemic scleroderma	0.000453	0.000453	CcSEcCtD
Temozolomide—Depression—Methotrexate—systemic scleroderma	0.000452	0.000452	CcSEcCtD
Temozolomide—Flushing—Prednisone—systemic scleroderma	0.000452	0.000452	CcSEcCtD
Temozolomide—Headache—Azathioprine—systemic scleroderma	0.00045	0.00045	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00045	0.00045	CcSEcCtD
Temozolomide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00045	0.00045	CcSEcCtD
Temozolomide—Dizziness—Leflunomide—systemic scleroderma	0.000449	0.000449	CcSEcCtD
Temozolomide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000444	0.000444	CcSEcCtD
Temozolomide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000443	0.000443	CcSEcCtD
Temozolomide—Stomatitis—Methotrexate—systemic scleroderma	0.000442	0.000442	CcSEcCtD
Temozolomide—Angiopathy—Prednisone—systemic scleroderma	0.000442	0.000442	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000441	0.000441	CcSEcCtD
Temozolomide—Immune system disorder—Prednisone—systemic scleroderma	0.00044	0.00044	CcSEcCtD
Temozolomide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000437	0.000437	CcSEcCtD
Temozolomide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000437	0.000437	CcSEcCtD
Temozolomide—Vomiting—Leflunomide—systemic scleroderma	0.000431	0.000431	CcSEcCtD
Temozolomide—Alopecia—Prednisone—systemic scleroderma	0.000431	0.000431	CcSEcCtD
Temozolomide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000429	0.000429	CcSEcCtD
Temozolomide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000429	0.000429	CcSEcCtD
Temozolomide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Temozolomide—Rash—Leflunomide—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Temozolomide—Dermatitis—Leflunomide—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Temozolomide—Mental disorder—Prednisone—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Temozolomide—Nausea—Azathioprine—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Temozolomide—Headache—Leflunomide—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Temozolomide—Malnutrition—Prednisone—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Temozolomide—Erythema—Prednisone—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Temozolomide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000421	0.000421	CcSEcCtD
Temozolomide—Asthenia—Lisinopril—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Temozolomide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Temozolomide—Pruritus—Lisinopril—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Temozolomide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000411	0.000411	CcSEcCtD
Temozolomide—Haemoglobin—Methotrexate—systemic scleroderma	0.000409	0.000409	CcSEcCtD
Temozolomide—Rash—Mycophenolic acid—systemic scleroderma	0.000408	0.000408	CcSEcCtD
Temozolomide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000408	0.000408	CcSEcCtD
Temozolomide—Haemorrhage—Methotrexate—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Temozolomide—Hepatitis—Methotrexate—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Temozolomide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000406	0.000406	CcSEcCtD
Temozolomide—Headache—Mycophenolic acid—systemic scleroderma	0.000405	0.000405	CcSEcCtD
Temozolomide—Pharyngitis—Methotrexate—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Temozolomide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Temozolomide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Temozolomide—Nausea—Leflunomide—systemic scleroderma	0.000403	0.000403	CcSEcCtD
Temozolomide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000402	0.000402	CcSEcCtD
Temozolomide—Vision blurred—Prednisone—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Temozolomide—Urethral disorder—Methotrexate—systemic scleroderma	0.000399	0.000399	CcSEcCtD
Temozolomide—Diarrhoea—Lisinopril—systemic scleroderma	0.000399	0.000399	CcSEcCtD
Temozolomide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Temozolomide—Visual impairment—Methotrexate—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Temozolomide—Anaemia—Prednisone—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Temozolomide—Agitation—Prednisone—systemic scleroderma	0.00039	0.00039	CcSEcCtD
Temozolomide—Angioedema—Prednisone—systemic scleroderma	0.000388	0.000388	CcSEcCtD
Temozolomide—Dizziness—Lisinopril—systemic scleroderma	0.000385	0.000385	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000385	0.000385	CcSEcCtD
Temozolomide—Nausea—Mycophenolic acid—systemic scleroderma	0.000384	0.000384	CcSEcCtD
Temozolomide—Malaise—Prednisone—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Temozolomide—Vertigo—Prednisone—systemic scleroderma	0.000381	0.000381	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—systemic scleroderma	0.000381	0.000381	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—systemic scleroderma	0.00038	0.00038	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000378	0.000378	CcSEcCtD
Temozolomide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000376	CcSEcCtD
Temozolomide—Vomiting—Lisinopril—systemic scleroderma	0.000371	0.000371	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—systemic scleroderma	0.000369	0.000369	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—systemic scleroderma	0.000368	0.000368	CcSEcCtD
Temozolomide—Rash—Lisinopril—systemic scleroderma	0.000368	0.000368	CcSEcCtD
Temozolomide—Convulsion—Prednisone—systemic scleroderma	0.000368	0.000368	CcSEcCtD
Temozolomide—Dermatitis—Lisinopril—systemic scleroderma	0.000367	0.000367	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000367	0.000367	CcSEcCtD
Temozolomide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Temozolomide—Hypertension—Prednisone—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Temozolomide—Chills—Methotrexate—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Temozolomide—Headache—Lisinopril—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Temozolomide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000361	CcSEcCtD
Temozolomide—Arthralgia—Prednisone—systemic scleroderma	0.000361	0.000361	CcSEcCtD
Temozolomide—Myalgia—Prednisone—systemic scleroderma	0.000361	0.000361	CcSEcCtD
Temozolomide—Anxiety—Prednisone—systemic scleroderma	0.00036	0.00036	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—systemic scleroderma	0.00036	0.00036	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000359	0.000359	CcSEcCtD
Temozolomide—Discomfort—Prednisone—systemic scleroderma	0.000357	0.000357	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—systemic scleroderma	0.000357	0.000357	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—systemic scleroderma	0.000354	0.000354	CcSEcCtD
Temozolomide—Erythema—Methotrexate—systemic scleroderma	0.000354	0.000354	CcSEcCtD
Temozolomide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—systemic scleroderma	0.000347	0.000347	CcSEcCtD
Temozolomide—Nausea—Lisinopril—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Temozolomide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Temozolomide—Oedema—Prednisone—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Temozolomide—Infection—Prednisone—systemic scleroderma	0.000344	0.000344	CcSEcCtD
Temozolomide—Back pain—Methotrexate—systemic scleroderma	0.000343	0.000343	CcSEcCtD
Temozolomide—Nervous system disorder—Prednisone—systemic scleroderma	0.000339	0.000339	CcSEcCtD
Temozolomide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000338	CcSEcCtD
Temozolomide—Skin disorder—Prednisone—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Temozolomide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000335	0.000335	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—systemic scleroderma	0.000334	0.000334	CcSEcCtD
Temozolomide—Anorexia—Prednisone—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000329	0.000329	CcSEcCtD
Temozolomide—Anaemia—Methotrexate—systemic scleroderma	0.000328	0.000328	CcSEcCtD
Temozolomide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000325	CcSEcCtD
Temozolomide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000322	CcSEcCtD
Temozolomide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000322	CcSEcCtD
Temozolomide—Headache—Mycophenolate mofetil—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Temozolomide—Malaise—Methotrexate—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—systemic scleroderma	0.000318	0.000318	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—systemic scleroderma	0.000317	0.000317	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000315	0.000315	CcSEcCtD
Temozolomide—Insomnia—Prednisone—systemic scleroderma	0.000313	0.000313	CcSEcCtD
Temozolomide—Paraesthesia—Prednisone—systemic scleroderma	0.000311	0.000311	CcSEcCtD
Temozolomide—Cough—Methotrexate—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—systemic scleroderma	0.000307	0.000307	CcSEcCtD
Temozolomide—Dyspepsia—Prednisone—systemic scleroderma	0.000305	0.000305	CcSEcCtD
Temozolomide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000303	0.000303	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—systemic scleroderma	0.000302	0.000302	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—systemic scleroderma	0.000302	0.000302	CcSEcCtD
Temozolomide—Decreased appetite—Prednisone—systemic scleroderma	0.000301	0.000301	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.0003	0.0003	CcSEcCtD
Temozolomide—Fatigue—Prednisone—systemic scleroderma	0.000298	0.000298	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—systemic scleroderma	0.000298	0.000298	CcSEcCtD
Temozolomide—Constipation—Prednisone—systemic scleroderma	0.000296	0.000296	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—systemic scleroderma	0.000292	0.000292	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000289	0.000289	CcSEcCtD
Temozolomide—Infection—Methotrexate—systemic scleroderma	0.000287	0.000287	CcSEcCtD
Temozolomide—Feeling abnormal—Prednisone—systemic scleroderma	0.000285	0.000285	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000284	0.000284	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000283	0.000283	CcSEcCtD
Temozolomide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000283	0.000283	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—systemic scleroderma	0.000281	0.000281	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00028	0.00028	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Temozolomide—Urticaria—Prednisone—systemic scleroderma	0.000275	0.000275	CcSEcCtD
Temozolomide—Abdominal pain—Prednisone—systemic scleroderma	0.000274	0.000274	CcSEcCtD
Temozolomide—Body temperature increased—Prednisone—systemic scleroderma	0.000274	0.000274	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000264	0.000264	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—systemic scleroderma	0.000262	0.000262	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—systemic scleroderma	0.00026	0.00026	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—systemic scleroderma	0.000258	0.000258	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—systemic scleroderma	0.000257	0.000257	CcSEcCtD
Temozolomide—Hypersensitivity—Prednisone—systemic scleroderma	0.000255	0.000255	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—systemic scleroderma	0.000255	0.000255	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—systemic scleroderma	0.000252	0.000252	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00025	0.00025	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—systemic scleroderma	0.000249	0.000249	CcSEcCtD
Temozolomide—Asthenia—Prednisone—systemic scleroderma	0.000248	0.000248	CcSEcCtD
Temozolomide—Pain—Methotrexate—systemic scleroderma	0.000247	0.000247	CcSEcCtD
Temozolomide—Pruritus—Prednisone—systemic scleroderma	0.000245	0.000245	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000238	0.000238	CcSEcCtD
Temozolomide—Diarrhoea—Prednisone—systemic scleroderma	0.000237	0.000237	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000237	0.000237	CcSEcCtD
Temozolomide—Urticaria—Methotrexate—systemic scleroderma	0.00023	0.00023	CcSEcCtD
Temozolomide—Dizziness—Prednisone—systemic scleroderma	0.000229	0.000229	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—systemic scleroderma	0.000229	0.000229	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—systemic scleroderma	0.000229	0.000229	CcSEcCtD
Temozolomide—Vomiting—Prednisone—systemic scleroderma	0.00022	0.00022	CcSEcCtD
Temozolomide—Rash—Prednisone—systemic scleroderma	0.000218	0.000218	CcSEcCtD
Temozolomide—Dermatitis—Prednisone—systemic scleroderma	0.000218	0.000218	CcSEcCtD
Temozolomide—Headache—Prednisone—systemic scleroderma	0.000217	0.000217	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000213	0.000213	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—systemic scleroderma	0.000208	0.000208	CcSEcCtD
Temozolomide—Nausea—Prednisone—systemic scleroderma	0.000206	0.000206	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—systemic scleroderma	0.000205	0.000205	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—systemic scleroderma	0.000198	0.000198	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—systemic scleroderma	0.000191	0.000191	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—systemic scleroderma	0.000184	0.000184	CcSEcCtD
Temozolomide—Rash—Methotrexate—systemic scleroderma	0.000182	0.000182	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—systemic scleroderma	0.000182	0.000182	CcSEcCtD
Temozolomide—Headache—Methotrexate—systemic scleroderma	0.000181	0.000181	CcSEcCtD
Temozolomide—Nausea—Methotrexate—systemic scleroderma	0.000172	0.000172	CcSEcCtD
